EUVIMEDEUVIMED entdecken
Übersichtsarbeit

To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?

Matthew Lee, Shuai Wang, Lova Sun, Balazs Halmos

Clinical Lung Cancer · 2026-05 · 27 (4) · 29-40

DOI: 10.1016/j.cllc.2026.03.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lung Cancer, 2026-05. Verfasst von Matthew Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine Bronx, New York, NY; Department o…. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has transformed the treatment landscape of advanced and metastatic non-small cell lung cancer, providing durable survival benefits for a subset of patients. Despite widespread adoption of immune checkpoint inhibitors as frontline therapy, the optimal duration of treatment remains uncertain. Current practice often limits therapy to 2 years or continues indefinitely until progression based on landmark clinical trials that arbitrarily chose these timepoints, and it is not biologically based. Unfortunately, there is still limited prospective or clinical trial evidence to guide such decisions. Retrospective studies have suggested that discontinuation at 2 years may not compromise outcomes, but also raise concerns about balancing efficacy with cumulative toxicities and financial burden. This review provides updated data and ongoing trials seeking to answer these questions, along with potential emerging biomarkers, including circulating tumor DNA (ctDNA) and imaging with positron emission tomography/computed tomography that can help risk-stratify and guide and refine treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmunotherapyCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsHumansBiomarkers, TumorTreatment Interruption

Stichwörter der Autor:innen

BiomarkersDuration of treatmentImmune checkpoint inhibitorsToxicitiesToxicity

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine Bronx, New York, NY; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensi…
  • Department of Medical Oncology Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine Bronx, New York, NY; Department of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN.
  • Division of Hematology/Oncology Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Medical Oncology Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine Bronx, New York, NY.

Zitieren

APA

Lee, M., Wang, S., Sun, L., & Halmos, B. (2026). To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?. Clinical Lung Cancer, 27(4), 29-40. https://doi.org/10.1016/j.cllc.2026.03.012

Vancouver

Lee M, Wang S, Sun L, Halmos B. To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?. Clinical Lung Cancer. 2026;27(4):29-40. doi:10.1016/j.cllc.2026.03.012

BibTeX
@article{Lee2026,
  author = {Lee, Matthew and Wang, Shuai and Sun, Lova and Halmos, Balazs},
  title = {To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {29--40},
  doi = {10.1016/j.cllc.2026.03.012}
}
Kostenlos starten →